Association between acetaminophen metabolites and CYP2E1 DNA methylation level in neonate cord blood in the Boston Birth Cohort.


Journal

Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977

Informations de publication

Date de publication:
18 08 2023
Historique:
received: 08 03 2023
accepted: 09 08 2023
medline: 21 8 2023
pubmed: 19 8 2023
entrez: 18 8 2023
Statut: epublish

Résumé

Acetaminophen is a commonly used medication by pregnant women and is known to cross the placenta. However, little is known about the biological mechanisms that regulate acetaminophen in the developing offspring. Cytochrome 2E1 (CYP2E1) is the primary enzyme responsible for the conversion of acetaminophen to its toxic metabolite. Ex vivo studies have shown that the CYP2E1 gene expression in human fetal liver and placenta is largely controlled by DNA methylation (DNAm) at CpG sites located in the gene body of CYP2E1 at the 5' end. To date, no population studies have examined the association between acetaminophen metabolite and fetal DNAm of CYP2E1 at birth. We utilized data from the Boston Birth Cohort (BBC) which represents an urban, low-income, racially and ethnically diverse population in Boston, Massachusetts. Acetaminophen metabolites were measured in the cord plasma of newborns enrolled in BBC between 2003 and 2013 using liquid chromatography-tandem mass spectrometry. DNAm at 28 CpG sites of CYP2E1 was measured by Illumina Infinium MethylationEPIC BeadChip. We used linear regression to identify differentially methylated CpG sites and the "DiffVar" method to identify differences in methylation variation associated with the detection of acetaminophen, adjusting for cell heterogeneity and batch effects. The false discovery rate (FDR) was calculated to account for multiple comparisons. Among the 570 newborns included in this study, 96 (17%) had detectable acetaminophen in cord plasma. We identified 7 differentially methylated CpGs (FDR < 0.05) associated with the detection of acetaminophen and additional 4 CpGs showing a difference in the variation of methylation (FDR < 0.05). These CpGs were all located in the gene body of CYP2E1 at the 5' end and had a 3-6% lower average methylation level among participants with detectable acetaminophen compared to participants without. The CpG sites we identified overlap with previously identified DNase hypersensitivity and open chromatin regions in the ENCODE project, suggesting potential regulatory functions. In a US birth cohort, we found detection of cord biomarkers of acetaminophen was associated with DNAm level of CYP2E1 in cord blood. Our findings suggest that DNA methylation of CYP2E1 may be an important regulator of acetaminophen levels in newborns.

Sections du résumé

BACKGROUND
Acetaminophen is a commonly used medication by pregnant women and is known to cross the placenta. However, little is known about the biological mechanisms that regulate acetaminophen in the developing offspring. Cytochrome 2E1 (CYP2E1) is the primary enzyme responsible for the conversion of acetaminophen to its toxic metabolite. Ex vivo studies have shown that the CYP2E1 gene expression in human fetal liver and placenta is largely controlled by DNA methylation (DNAm) at CpG sites located in the gene body of CYP2E1 at the 5' end. To date, no population studies have examined the association between acetaminophen metabolite and fetal DNAm of CYP2E1 at birth.
METHODS
We utilized data from the Boston Birth Cohort (BBC) which represents an urban, low-income, racially and ethnically diverse population in Boston, Massachusetts. Acetaminophen metabolites were measured in the cord plasma of newborns enrolled in BBC between 2003 and 2013 using liquid chromatography-tandem mass spectrometry. DNAm at 28 CpG sites of CYP2E1 was measured by Illumina Infinium MethylationEPIC BeadChip. We used linear regression to identify differentially methylated CpG sites and the "DiffVar" method to identify differences in methylation variation associated with the detection of acetaminophen, adjusting for cell heterogeneity and batch effects. The false discovery rate (FDR) was calculated to account for multiple comparisons.
RESULTS
Among the 570 newborns included in this study, 96 (17%) had detectable acetaminophen in cord plasma. We identified 7 differentially methylated CpGs (FDR < 0.05) associated with the detection of acetaminophen and additional 4 CpGs showing a difference in the variation of methylation (FDR < 0.05). These CpGs were all located in the gene body of CYP2E1 at the 5' end and had a 3-6% lower average methylation level among participants with detectable acetaminophen compared to participants without. The CpG sites we identified overlap with previously identified DNase hypersensitivity and open chromatin regions in the ENCODE project, suggesting potential regulatory functions.
CONCLUSIONS
In a US birth cohort, we found detection of cord biomarkers of acetaminophen was associated with DNAm level of CYP2E1 in cord blood. Our findings suggest that DNA methylation of CYP2E1 may be an important regulator of acetaminophen levels in newborns.

Identifiants

pubmed: 37596607
doi: 10.1186/s13148-023-01551-4
pii: 10.1186/s13148-023-01551-4
pmc: PMC10439592
doi:

Substances chimiques

Cytochrome P-450 CYP2E1 EC 1.14.13.-
Acetaminophen 362O9ITL9D

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S. Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

132

Subventions

Organisme : NIAID NIH HHS
ID : R21 AI154233
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD098232
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES031521
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD041702
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES031272
Pays : United States
Organisme : NIEHS NIH HHS
ID : U01 ES034983
Pays : United States
Organisme : NICHD NIH HHS
ID : R21 HD066471
Pays : United States

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
Hum Mol Genet. 2019 Aug 15;28(16):2659-2674
pubmed: 31009952
J Biol Chem. 1996 May 17;271(20):12063-7
pubmed: 8662637
Genome Biol. 2014 Sep 23;15(9):465
pubmed: 25245051
Br J Clin Pharmacol. 1984 Aug;18(2):201-6
pubmed: 6487458
J Pharmacol Exp Ther. 2003 Oct;307(1):402-7
pubmed: 14500779
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Pharmacol Toxicol. 1998 Nov;83(5):183-7
pubmed: 9834965
Crit Care Clin. 2012 Oct;28(4):499-516
pubmed: 22998987
Curr Protoc Mol Biol. 2012 Apr;Chapter 30:Unit 30.2.1-24
pubmed: 22470063
Eur J Biochem. 1996 Jun 1;238(2):476-83
pubmed: 8681961
Mol Cell Biol. 1990 Sep;10(9):4495-505
pubmed: 2388615
J Clin Transl Hepatol. 2016 Jun 28;4(2):131-42
pubmed: 27350943
Environ Health Perspect. 2017 Apr;125(4):511-526
pubmed: 28362264
Environ Epigenet. 2019 Aug 06;5(2):dvz010
pubmed: 31404209
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Environ Epigenet. 2022 Feb 02;8(1):dvac002
pubmed: 35317219
Am J Perinatol. 2017 May;34(6):541-543
pubmed: 27806383
Am J Obstet Gynecol. 2005 Sep;193(3 Pt 1):771-7
pubmed: 16150273
Diabetes Care. 2020 Jan;43(1):98-105
pubmed: 31601636
Epigenetics. 2016 May 3;11(5):354-62
pubmed: 27019159
Clin Epigenetics. 2017 Aug 2;9:77
pubmed: 28785368
BMC Bioinformatics. 2010 Nov 30;11:587
pubmed: 21118553
Precis Nutr. 2022 Aug 18;1(2):e00011
pubmed: 37745944
Bioinformatics. 2017 Feb 15;33(4):558-560
pubmed: 28035024
Hypertens Pregnancy. 2016 Nov;35(4):510-519
pubmed: 27322489
DNA Cell Biol. 1995 Apr;14(4):285-93
pubmed: 7710685
Methods Mol Biol. 2016;1418:335-51
pubmed: 27008022
Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45
pubmed: 26553804
Nucleic Acids Res. 2013 Jan;41(Database issue):D56-63
pubmed: 23193274
Pediatrics. 1975 Jun;55(6):895
pubmed: 1134892
Curr Opin Infect Dis. 2002 Jun;15(3):301-6
pubmed: 12015466
Biochem Pharmacol. 1992 Apr 15;43(8):1876-9
pubmed: 1575782
Ann N Y Acad Sci. 2010 Sep;1205:118-22
pubmed: 20840262
Acta Obstet Gynecol Scand. 2011 Jun;90(6):564-73
pubmed: 21355860
Am J Obstet Gynecol. 1986 Dec;155(6):1353-6
pubmed: 3789044

Auteurs

Yijun Li (Y)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street W6509, Baltimore, MD, 21205, USA.

Xiumei Hong (X)

Center on the Early Life Origins of Disease, Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Liming Liang (L)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Xiaobin Wang (X)

Center on the Early Life Origins of Disease, Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Christine Ladd-Acosta (C)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street W6509, Baltimore, MD, 21205, USA. claddac1@jh.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH